Article in Blood cancer journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Emily Ayers *Division of Hematology and Oncology and Comprehensive Cancer Center, University of Virginia School of Medicine, Charlottesville, VA, USA. eca2t@virginia.edu.ORCID 0000-0003-3748-4507
Glenda Canderan *Division of Asthma, Allergy and Immunology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA. gc8jw@virginia.edu.ORCID 0000-0001-8388-9930
Michael E WilliamsDivision of Hematology and Oncology and Comprehensive Cancer Center, University of Virginia School of Medicine, Charlottesville, VA, USA.
Behnam KeshavarzDivision of Asthma, Allergy and Immunology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.
Craig A PortellDivision of Hematology and Oncology and Comprehensive Cancer Center, University of Virginia School of Medicine, Charlottesville, VA, USA.
Jeffrey M WilsonDivision of Asthma, Allergy and Immunology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.
Judith A WoodfolkDivision of Asthma, Allergy and Immunology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.
Funding
Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Dina Gould Halme · 1987 to 2026
$72.1M
Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in HumansU01AI125056 · NIAID · UNIVERSITY OF VIRGINIA · PI WOODFOLK, JUDITH A · 2016 to 2020
$4.1M
Protective and Pathogenic T Cells Responding to SARS-CoV-2 in Health and DiseaseR21AI160334 · NIAID · UNIVERSITY OF VIRGINIA · PI WOODFOLK, JUDITH A · 2021 to 2022
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
In-depth cellular and humoral dynamics of the response to COVID-19 vaccine booster in patients with chronic B-cell neoplasms. · full record | OpenQuestion